Compare GFAI & HOTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GFAI | HOTH |
|---|---|---|
| Founded | 2018 | 2017 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.4M | 16.6M |
| IPO Year | N/A | 2019 |
| Metric | GFAI | HOTH |
|---|---|---|
| Price | $0.59 | $1.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $4.50 | $4.50 |
| AVG Volume (30 Days) | ★ 341.8K | 270.2K |
| Earning Date | 09-23-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $36,987,715.00 | N/A |
| Revenue This Year | $5.66 | N/A |
| Revenue Next Year | $4.69 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 4.38 | N/A |
| 52 Week Low | $0.54 | $0.66 |
| 52 Week High | $2.20 | $2.12 |
| Indicator | GFAI | HOTH |
|---|---|---|
| Relative Strength Index (RSI) | 36.79 | 44.66 |
| Support Level | $0.60 | $1.01 |
| Resistance Level | $0.80 | $1.12 |
| Average True Range (ATR) | 0.04 | 0.05 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 31.39 | 53.27 |
Guardforce AI Co Ltd is an integrated solution provider, specializing in security solutions, and also focuses on implementing AI and robotics solutions to improve business operational efficiency and sales and marketing processes, especially for the retail and travel industry in the Asia Pacific. The company's operating business segments include Secured Logistics, AI & Robotics Solution Business, General Security Solutions, and Corporate and others. A majority of its revenue is generated from the Secured Logistics segment, which includes services like cash-in-transit, dedicated vehicles to banks, ATM management, cash center operations, cash processing, coin processing, cheque center, and cash deposit machine solutions.
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).